Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, the sector…#goldmansachs #novonordisk #nvo #novonordisks #amycretin #novo #wegovy #amgen #amgn #easily
Source: Reuters: Health - Category: Consumer Health News Source Type: news